SILVER SPRING, Md.,
March 4, 2013 /PRNewswire/
-- Pharmagen, Inc. (OTCBB: PHRX) (the "Company" or
"Pharmagen") announces it has entered into a financial advisory
agreement with Merriman Capital, Inc., a wholly owned subsidiary of
Merriman Holdings, Inc. (OTCQX: MERR). Merriman Capital, Inc.
is a registered investment bank providing equity and options
execution services, market making, and differentiated research for
high growth companies. The firm also provides capital raising,
advisory, and M&A services. Under the terms of the agreement,
Merriman has agreed to provide Pharmagen with a wide range of
services from equity research coverage, participation in the
Merriman's annual investor conference, non-deal road shows and
eligibility criteria for admission to NASDAQ and other exchanges.
Merriman is the leading investment banking firm for micro-cap
companies.
"Pharmagen continues to demonstrate to our shareholders that we
are building a company for the long term. Merriman is the leading
advisory firm to companies in our market cap range and we're going
to work very hard over the coming year to build an institutional
shareholder base. Merriman is going to ensure that we're doing it
in a way that will resonate with that community," said Mackie A. Barch, CEO of Pharmagen.
About Pharmagen
Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and
operating divisions Pharmagen Laboratories, Inc., Pharmagen
Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader
in innovative solutions to the nations sterile pharmaceutical
crisis. With a multifaceted approach, Pharmagen is meeting the
demand of health provider market through dynamic, independent
wholesale, compounding, and innovative IT solutions.
Nationally focused, Pharmagen is a dynamic distributor of specialty
drugs, compounding and admix pharmacy and producer of
over-the-counter ("OTC") branded multivitamins to the healthcare
provider market. Pharmagen currently functions as a just-in-time
source of supply for hospitals for those products that are
hard-to-find due to drug manufacturers' production shortages.
About Merriman Capital, Inc.
Merriman Capital, Inc. is a corporate advisory-focused
registered investment bank that provides equity and options
execution services, market making, and differentiated research for
high growth companies. The firm also provides capital formation,
advisory, and M&A services. Merriman Capital, Inc. is a wholly
owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR) and is
the leading investment banking firm for OTCQX companies. For more
information, please go to http://www.merrimanco.com/.
Merriman Capital, Inc. is a registered broker-dealer and member
of The Financial Industry Regulatory Authority (FINRA)
http://www.finra.org/ and the Securities Investor Protection
Corporation (SIPC) http://www.sipc.org/.
Contact: 888-264-4597 or info@pharmagenrx.com
Safe Harbor Statement
Information in this document constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The words
"forecast", "anticipate", "estimate", "project", "intend",
"expect", "should", "believe", and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Pharmagen actual
results, performance (financial or operating) or achievements to
differ from the future results, performance (financial or
operating) or achievements expressed or implied by such
forward-looking statements. The risks, uncertainties and
other factors are more fully discussed in Pharmagen' filings with
the U.S. Securities and Exchange Commission. All
forward-looking statements attributable to Pharmagen herein are
expressly qualified in their entirety by the above-mentioned
cautionary statement. Pharmagen disclaims any obligation to
update forward-looking statements contained in this estimate,
except as may be required by law.
SOURCE Pharmagen, Inc.
